Blaze Bioscience Lands $3,500,000 Series A Funding
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=05b5c065-58c3-4117-9e0e-fa5b5cdd133e&Preview=1 -
Date
2/22/2013 -
Company Name
Blaze Bioscience -
Mailing Address
530 Fairview Avenue North Seattle, WA 98109 -
Company Description
For years, surgeons have been searching for better intraoperative tools to more effectively treat cancer. When removing tumors, the ability to precisely identify them is of paramount importance. If too little tissue is removed, cancer cells are left behind to grow and spread. If too much tissue is removed, the patient may experience significant disabilities and reduced quality of life. -
Website
http://www.blazebioscience.com -
Transaction Type
Venture Equity -
Transaction Amount
$3,500,000 -
Transaction Round
Series A -
Proceeds Purposes
The funding (an add-on to previously raising $5 million in its Series A) will support the advancement of Blaze’s Tumor PaintTM product candidate, BLZ-100, into clinical development for use in surgery in multiple solid tumor types. The resources have also supported the expansion of Blaze’s leadership team and establishment of corporate headquarters, including laboratory space, in the South Lake Union area of Seattle. -
M&A Terms
-
Venture Investor
Undisclosed
